COMPOSITION PHARMACEUTIQUE DESTINEE A ETRE UTILISEE DANS LA PREVENTION ET/OU LE TRAITEMENT D'UNE MALADIE QUI SE DEVELOPPE OU PROGRESSE EN RAISON D'UNE BAISSE OU D'UNE PERTE D'ACTIVITE DU FACTEUR VIII DE COAGULATION SANGUINE ET/OU DU FACTEUR VIII DE COAGULATION SANGUINE ACTIVE
The present invention is based on the discovery that by administering a predetermined dosing regimen of a pharmaceutical composition that comprises a bi-specific antigen-binding molecule that recognizes blood coagulation factor IX and/or activated blood coagulation factor IX and blood coagulation factor X and/or activated blood coagulation factor X, it is possible to more effectively prevent and/or treat a disease that develops or progresses as a result of a decrease or loss of the activity of blood coagulation factor VIII and/or activated blood coagulation factor VIII.
